Search Results
449 results found-
Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.
https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza -
Since the COVID-19 pandemic, there has been a significant drop in influenza immunization rates and high levels of influenza-related illness, underscoring that flu is an ongoing threat.
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
From April 24-30, public health officials raise awareness about the protection vaccines provide and their potential to improve global health. This year, the World Health Organization (WHO) celebrates 50 years of its Expanded Programme on Immunization.
https://www.csl.com/we-are-csl/vita-original-stories/2024/world-immunization-week-2024 -
1 Additionally, enhanced vaccines are projected to further reduce the strain on hospitals and intensive care units by 10-15%, supporting bed availability during a potential COVID-19 endemic wave.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
Circulation and Seasonality of Epidemics of Influenza, RSV and Other Respiratory Viruses Before, During, and After the COVID-19 Pandemic:
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile. "
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
https://www.csl.com/research-and-development/product-pipeline -
CSL Seqirus has started shipping influenza vaccines to health care providers in the United States, helping them get prepared for the upcoming flu season.
https://www.csl.com/we-are-csl/vita-original-stories/2023/now-shipping-flu-vaccines